Does mSH3 expression influence the sensitivity of colon cancer HCT116 cell line to oxaliplatin and poly ( ADP-ribose ) polymerase ( PARP ) inhibitor as monotherapy or in combination?
Restoring of MSH3 expression by cDNA transfection, rather than by chromosome transfer, did not affect colon cancer sensitivity to oxaliplatin or PARPi monotherapy; PARP-1 levels seemed to be more crucial for the outcome of PARPi monotherapy.
CL has modest predictive accuracy in women with threatened PTL, regardless of GA at presentation. However, the optimal cutoff of CL for the purpose of clinical decision making in women with PTL needs to be adjusted based on GA at presentation.